Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PN-032
- Development stage
- Discontinued
- Lead developer
- Polyneuron Pharmaceuticals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Parenteral, Injection
01
Overview
PN-032 is a recombinant polypeptide drug candidate developed by Polyneuron Pharmaceuticals. It belongs to the class of glycopeptides and immunotherapies and acts as an immunosuppressant. The primary therapeutic area under investigation is hematopoietic stem cell transplantation, with additional research interest in autoimmune disorders such as IgA nephropathy and transplant rejection. As of the latest updates, its highest development phase is preclinical. The mechanism of action involves immunosuppression; however, specific molecular targets have not been disclosed in public sources[1][2].
- Other names
- anti-B blood group antibodies glycopolymer
Beyond the preview
Go deeper on PN-032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PN-032.